Showing results (21-30 of 120) with videos related to
Sort By:
Pageof 12
Drug Discovery Today|March 8, 2003
Cancer immunotherapy: an embarrassment of riches?Mike Whelan, Joseph Whelan, Nick Russell, et al.World Journal of Surgery|December 25, 2013
Surgical management of intraabdominal metastases from melanoma: role of the neutrophil to lymphocyte ratio as a potential prognostic factorFerdinando C M Cananzi, Angus Dalgleish, Satvinder MudanJournal of Immunological Methods|May 14, 2005
Cryopreserved dendritic cells for intratumoral immunotherapy do not require re-culture prior to human vaccinationJustin John, Angus Dalgleish, Alan Melcher, et al.Personalized Medicine|May 23, 2018
Biomarkers for development of cancer vaccinesMike Whelan, Graham Ball, Chris Beattie, et al.Investigational New Drugs|January 21, 2014
Rituximab for treating CD20+ prostate cancer with generalized lymphadenopathy: a case report and review of the literatureAngus Dalgleish, Peter Featherstone, Viatcheslav Vlassov, et al.BJU International|May 17, 2005
Immunotherapy of murine prostate cancer using whole tumour cells killed ex vivo by cytosine deaminase/5-fluorocytosine suicide-gene therapyHardev S Pandha, Dorthe Cook, Rebecca Greenhalgh, et al.Scientific Reports|February 9, 2019
In vitro culture with gemcitabine augments death receptor and NKG2D ligand expression on tumour cellsAndrew M Gravett, Angus G Dalgleish, John CopierFEMS Microbiology Letters|September 11, 2004
Novel strains of Salmonella typhimurium as potential vectors for gene deliveryAgnieszka Michael, Richard Stratford, Shahid Khan, et al.Cancer Gene Therapy|April 2, 2005
Immunotherapy of murine prostate cancer using whole tumor cells killed ex vivo by herpes simplex viral thymidine kinase/ganciclovir suicide gene therapyHardev Pandha, Jonathan Eaton, Rebecca Greenhalgh, et al.Frontiers in Immunology|January 30, 2023
Releasing the restraints of Vγ9Vδ2 T-cells in cancer immunotherapyLaura A Ridgley, Jonathan Caron, Angus Dalgleish, et al.Pageof 12